Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
A national, multicenter, randmised double blind study with parallell arms. 360 patients with grass induced allergic rhinitis will be open randomised 1:2 to 3 years Grazax sublingual immunotherapy or 3 intralymphatic injections with ALK Alutard Timothy. In a second step, the ILIT group will be double blind randomised 1:1 to an intramuscular injection of Vitamin D Vicotrat or placebo, 4 week before the start of the intralymphatic treatment. The primary outcome measure is daily combined symptoms and medication scores during grass pollen season.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria only for ILIT group (due to vitamin D treatment)
agneta.j.karlsson@regionstockholm.se+46 72 580 29 63
laila.hellkvist@regionstockholm.se+46 72 469 46 07
amanj.saber@regionorebrolan.se
eirini.paziou@regionstockholm.se+46 8 123 723 96
laila.hellkvist@regionstockholm.se+46 72 469 46 07